CAJ | 학술논문

目的：观察以卡培他滨为主的联合化疗方案治疗对蒽环类或紫杉类耐药的晚期三阴性乳腺癌的疗效和不良反应。方法共有38例复发转移的三阴性乳腺癌患者入组，分别采用卡培他滨联合吉西他滨（GX方案）或长春瑞滨（NX方案）化疗。卡培他滨2.0 g/（m2/d），早晚各1次，餐后30 min口服，d1～14；长春瑞滨25 mg/m2，d1，8，静滴；吉西他滨1000 mg/m2，d1，8，静滴；21天为1个周期。结果38例患者共完成133个周期化疗，中位化疗周期为4个周期。本组总有效率（RR＝CR＋PR）为18.4％，临床获益率（CR＋PR＋SD）为44．7％。中位无进展生存（PFS）为7.6个月，中位总生存（OS）为12.5个月。两组化疗方案疗效无统计学差异。无化疗相关死亡病例，主要不良反应为骨髓抑制及手足综合症。结论以卡培他滨为主的两药联合方案，对晚期T NBC患者疗效有限，提示含卡培他滨的联合化疗方案可用于晚期三阴性乳腺癌，但能否作为首选方案尚需大样本、多中心的临床研究。
목적：관찰이잡배타빈위주적연합화료방안치료대은배류혹자삼류내약적만기삼음성유선암적료효화불량반응。방법공유38례복발전이적삼음성유선암환자입조，분별채용잡배타빈연합길서타빈（GX방안）혹장춘서빈（NX방안）화료。잡배타빈2.0 g/（m2/d），조만각1차，찬후30 min구복，d1～14；장춘서빈25 mg/m2，d1，8，정적；길서타빈1000 mg/m2，d1，8，정적；21천위1개주기。결과38례환자공완성133개주기화료，중위화료주기위4개주기。본조총유효솔（RR＝CR＋PR）위18.4％，림상획익솔（CR＋PR＋SD）위44．7％。중위무진전생존（PFS）위7.6개월，중위총생존（OS）위12.5개월。량조화료방안료효무통계학차이。무화료상관사망병례，주요불량반응위골수억제급수족종합증。결론이잡배타빈위주적량약연합방안，대만기T NBC환자료효유한，제시함잡배타빈적연합화료방안가용우만기삼음성유선암，단능부작위수선방안상수대양본、다중심적림상연구。
Objective To evaluate the clinical efficacy and tolerability of capecitabine-based combination chemotherapy in the treatment of the anthracycline and taxane-resistant metastatic TNBC .Methods All 38 patients with metastatic breast cancer were recruited to receive either GX regimen ( capecitabine 2.0 g/m2 ,bid ,d1-14 ,gemcitabine 1000mg/m2 ,d1 ,8 iv ) or NX regi-men (capecitabine 2.0 g/m2 ,bid ,d1-14 ,vinorelbine 25 mg/m2 ,d1 ,8 iv ) .There were twenty-one days in a cycle .Results All 38 patients completed 133 chemotherapy cycles with a four-cycle median per patients .The overall response rate (CR+ PR) was 18.4% and clinical benefit rate was (CR+ PR+SD) 44.7% .The median time of progression(PFS) was 7.6 months ,OS was 12.5 months .The efficacy between of different chemotherapy regimens wans not significantly different .No patient died due to chemotherapy .The main toxicity was myelosuppression and hand -foot syndrome .Conclusion The efficacy of capecitabine con-tained GX or NX regimen was relatively poor in mTNBC patients ,suggesting capecitabine -based combination chemotherapy may be considered to be acceptable ,but if it could be a preferred ,we need large sample and multi-center study .